Published • loading... • Updated
Vall d’Hebron Will Be a Pioneer in Vaccinating During the Treatment of Sclerosis
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
On the eve of the World Day of Multiple Sclerosis, a research led by Vall d’Hebron Hospital provides one of the most anticipated evidences by specialists and patients: live attenuated vaccines against measles, rubella, mumps and chickenpox do not increase the risk of outbreaks in people with multiple sclerosis. The study, carried out from the analysis of 369 patients followed in Cemcat between 2016 and 2024, strengthens the safety of vaccination…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
